CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: LINC00342 (ImmuneEditome ID:150759)

1. Gene summary of enriched editing regions for LINC00342

check button Gene summary
Gene informationGene symbol

LINC00342

Gene ID

150759

GeneSynonymsNCRNA00342
GeneCytomap

2q11.1

GeneTypencRNA
GeneDescription-
GeneModificationdate20230329
UniprotID.
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr2:95808691-95809194:-ENST00000412393.4ENSG00000232931.4LINC00342ncRNA_intronicAluJo,AluSxchr2:95808691-95809194:-.alignment
chr2:95808691-95809194:-ENST00000448494.1ENSG00000232931.4LINC00342ncRNA_intronicAluJo,AluSxchr2:95808691-95809194:-.alignment
chr2:95815308-95815905:-ENST00000448494.1ENSG00000232931.4LINC00342ncRNA_exonicL1PREC2chr2:95815308-95815905:-.alignment


Top

2. Tumor-specific enriched editing regions for LINC00342


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr2:95815308-95815905:-BRCAEER1.2634e-14image
ENSG00000232931.4,LINC00342BRCAEAG9.6750e-06image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000232931.4,LINC00342KIRPCliEAG5.1521e-032.6430e-030.4522image
chr2:95815308-95815905:-OVCliEER4.8018e-026.8299e-030.2371image
ENSG00000232931.4,LINC00342OVCliEAG4.7053e-021.0353e-020.2225image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for LINC00342


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr2:95815308-95815905:-PCPGEERENSG00000198563,DDX39B-0.51953.1464e-086.4217e-10-0.4666imageNACIN1;BUD13;CPSF6;CSTF2T;EIF4A3;EIF4G2;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28B;MOV10;NOP56;NOP58;PTBP1;RANGAP1;RBFOX2;RBM10;RBM47;SAFB2;SLTM;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TRA2A;U2AF1;UPF1;YTHDF1;ZNF184DDX39BB_cells_naiveGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr2:95815308-95815905:-PCPGEERENSG00000235245,RP11-122K13.12-0.48085.9670e-076.4193e-09-0.4414imageNCNBP;CSTF2T;DDX54;EIF4A3;FBL;FMR1;FUS;HNRNPA1;HNRNPUL1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28B;NOP56;NOP58;RBFOX2;RBM10;SAFB2;SLTM;SND1;SRSF1;SRSF7;SRSF9;TAF15;U2AF1;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_UV_RESPONSE_UP
chr2:95815308-95815905:-PCPGEERENSG00000167615,LENG8-0.47321.0974e-069.2254e-09-0.4372imageNACIN1;BUD13;CNBP;CPSF6;CSTF2T;DDX54;EIF4A3;EIF4G2;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28B;MOV10;NOP56;NOP58;PTBP1;RANGAP1;RBFOX2;RBM10;RBM47;SAFB2;SLTM;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TRA2A;U2AF1;UPF1;YTHDF1;ZNF184LENG8T_cells_CD4_memory_restingGSVA_HALLMARK_ADIPOGENESIS
chr2:95815308-95815905:-PCPGEERENSG00000198625,MDM4-0.46931.4284e-066.2528e-08-0.4143imageNACIN1;BUD13;CNBP;CPSF6;CSTF2T;DDX54;EIF4A3;EIF4G2;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28B;MOV10;NOP56;NOP58;PTBP1;RANGAP1;RBFOX2;RBM10;RBM47;SAFB2;SLTM;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TRA2A;U2AF1;UPF1;YTHDF1;ZNF184MDM4GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr2:95815308-95815905:-PCPGEERENSG00000162231,NXF1-0.46561.9049e-063.9620e-08-0.4199imageNACIN1;BUD13;CNBP;CPSF6;CSTF2T;DDX54;EIF4A3;EIF4G2;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28B;MOV10;NOP56;NOP58;PTBP1;RANGAP1;RBFOX2;RBM10;SAFB2;SLTM;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TRA2A;U2AF1;UPF1;YTHDF1;ZNF184NAB_cells_naiveGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr2:95815308-95815905:-PCPGEERENSG00000279989,RP11-158H5.2-0.43641.1650e-051.5746e-07-0.4026imageNNNAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr2:95815308-95815905:-PCPGEERENSG00000114857,NKTR-0.41414.1822e-056.3873e-08-0.4140imageNACIN1;BUD13;CNBP;CPSF6;CSTF2T;DDX54;EIF4A3;EIF4G2;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28B;MOV10;NOP56;NOP58;PTBP1;RANGAP1;RBFOX2;RBM10;RBM47;SAFB2;SLTM;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TRA2A;U2AF1;UPF1;YTHDF1;ZNF184NKTRB_cells_naiveGSVA_HALLMARK_GLYCOLYSIS
chr2:95815308-95815905:-PCPGEERENSG00000197912,SPG7-0.41294.7073e-051.0065e-07-0.4083imageNACIN1;BUD13;CNBP;CPSF6;CSTF2T;DDX54;EIF4A3;EIF4G2;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28B;MOV10;NOP56;NOP58;PTBP1;RANGAP1;RBFOX2;RBM10;RBM47;SAFB2;SLTM;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TRA2A;U2AF1;UPF1;YTHDF1;ZNF184NAMast_cells_restingGSVA_HALLMARK_PROTEIN_SECRETION
chr2:95815308-95815905:-PCPGEERENSG00000132424,PNISR-0.41244.8368e-051.6732e-07-0.4018imageNACIN1;BUD13;CNBP;CPSF6;CSTF2T;DDX54;EIF4A3;EIF4G2;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28B;MOV10;NOP56;NOP58;PTBP1;RANGAP1;RBFOX2;RBM10;RBM47;SAFB2;SLTM;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TRA2A;U2AF1;UPF1;YTHDF1;ZNF184NAB_cells_naiveGSVA_HALLMARK_GLYCOLYSIS
chr2:95815308-95815905:-PCPGEERENSG00000214021,TTLL3-0.40734.8419e-051.0940e-07-0.4072imageNBUD13;CNBP;CPSF6;CSTF2T;DDX54;EIF4A3;EIF4G2;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28B;MOV10;NOP56;NOP58;PTBP1;RANGAP1;RBFOX2;RBM10;SAFB2;SLTM;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TRA2A;U2AF1;UPF1;ZNF184NAB_cells_naiveGSVA_HALLMARK_GLYCOLYSIS

More results



Top

4. Enriched editing regions and immune related splicing for LINC00342


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000232931.4,LINC00342
PCPGEAGIRENSG00000166405.10chr118138271:8138347:8139966:8140186-0.31471.5718e-032.5887e-06-0.4140imageNADAR;CSTF2T;DGCR8;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPM;IGF2BP2;MBNL2;NOP56;NOP58;PTBP1;RBFOX2;TAF15;TARDBP;U2AF2NAB_cells_naiveGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING
ENSG00000232931.4,LINC00342
PCPGEAGIRENSG00000110583.8chr1163952402:63952565:63952755:63952839-0.34602.4151e-034.8728e-07-0.4047imageNADAR;AIFM1;AUH;BCCIP;BUD13;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LSM11;MBNL2;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RNF219;SAFB2;SF3A3;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;U2AF1;U2AF2;VIM;XRN2;YWHAG;ZNF184NANeutrophilsGSVA_HALLMARK_HEME_METABOLISM
chr2:95815308-95815905:-
PCPGEERIRENSG00000116001.11chr270224553:70227822:70229058:70229091-0.29227.6734e-035.6376e-06-0.4011imageNACIN1;BUD13;CNBP;CPSF6;CSTF2T;DDX54;EIF4A3;EIF4G2;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28B;MOV10;NOP56;NOP58;PTBP1;RANGAP1;RBFOX2;RBM10;RBM47;SAFB2;SLTM;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TRA2A;U2AF1;UPF1;YTHDF1;ZNF184TIA1B_cells_naiveGSVA_HALLMARK_UV_RESPONSE_UP
chr2:95815308-95815905:-
PCPGEERIRENSG00000103248.13chr1686542100:86542213:86546558:86546649-0.39044.6200e-051.2105e-06-0.4093imageNACIN1;BUD13;CNBP;CPSF6;CSTF2T;DDX54;EIF4A3;EIF4G2;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28B;MOV10;NOP56;NOP58;PTBP1;RANGAP1;RBFOX2;RBM10;SAFB2;SLTM;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TRA2A;U2AF1;UPF1;YTHDF1;ZNF184NAB_cells_naiveGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING
chr2:95815308-95815905:-
PCPGEERIRENSG00000135723.9chr1667231636:67231819:67232038:67232058-0.41754.6562e-054.2698e-07-0.4053imageNACIN1;BUD13;CNBP;CPSF6;CSTF2T;DDX54;EIF4A3;EIF4G2;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28B;MOV10;NOP56;NOP58;PTBP1;RANGAP1;RBFOX2;RBM10;SAFB2;SLTM;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TRA2A;U2AF1;UPF1;ZNF184NAGSVA_HALLMARK_HEME_METABOLISM
ENSG00000232931.4,LINC00342
PCPGEAGIRENSG00000132680.6chr1155916624:155916737:155917498:155917574-0.33961.0468e-038.1277e-07-0.4168imageNADAR;AIFM1;AUH;BCCIP;BUD13;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LSM11;MBNL2;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RNF219;SAFB2;SF3A3;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;U2AF1;U2AF2;VIM;XRN2;YWHAG;ZNF184NAMast_cells_restingGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING
chr2:95815308-95815905:-
PCPGEERIRENSG00000147854.12chr96497197:6498158:6499834:6499931-0.41992.1581e-053.2082e-07-0.4132imageNACIN1;BUD13;CNBP;CPSF6;CSTF2T;DDX54;EIF4A3;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28B;MOV10;NOP56;NOP58;PTBP1;RANGAP1;RBFOX2;RBM10;RBM47;SAFB2;SLTM;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TRA2A;U2AF1;UPF1;YTHDF1;ZNF184NAB_cells_naiveGSVA_HALLMARK_UV_RESPONSE_UP
chr2:95815308-95815905:-
PCPGEERIRENSG00000270011.2chr199378258:9379619:9380056:9380121-0.36329.8099e-052.1360e-06-0.4124imageNACIN1;BUD13;CNBP;CSTF2T;DDX54;EIF4A3;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28B;MOV10;NOP56;NOP58;PTBP1;RANGAP1;RBFOX2;RBM10;RBM47;SAFB2;SND1;SRSF1;SRSF7;TAF15;TARDBP;TRA2A;U2AF1;UPF1;YTHDF1;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_KRAS_SIGNALING_DN
chr2:95815308-95815905:-
PCPGEERIRENSG00000197114.7chr2063733218:63733739:63734644:63734824-0.37923.7401e-041.0185e-07-0.4301imageNACIN1;BUD13;CNBP;CPSF6;CSTF2T;DDX54;EIF4A3;EIF4G2;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28B;MOV10;NOP56;NOP58;PTBP1;RANGAP1;RBFOX2;RBM10;SAFB2;SLTM;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TRA2A;U2AF1;UPF1;YTHDF1;ZNF184NAB_cells_naiveGSVA_HALLMARK_FATTY_ACID_METABOLISM
chr2:95815308-95815905:-
PCPGEERIRENSG00000113593.7chr565567512:65567615:65569631:65569732-0.33537.8629e-043.2960e-06-0.4069imageNACIN1;BUD13;CNBP;CPSF6;CSTF2T;DDX54;EIF4A3;EIF4G2;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28B;MOV10;NOP56;NOP58;PTBP1;RANGAP1;RBFOX2;RBM10;RBM47;SAFB2;SLTM;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TRA2A;U2AF1;UPF1;ZNF184NAGSVA_HALLMARK_HEME_METABOLISM

More results



Top

5. Enriched editing regions and immune infiltration for LINC00342


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000232931.4,LINC00342BLCAEAGT_cells_follicular_helper1.6449e-020.3036image
chr2:95815308-95815905:-BRCAEERT_cells_CD4_memory_resting1.5369e-06-0.1878image
ENSG00000232931.4,LINC00342BRCAEAGT_cells_CD4_memory_resting2.6008e-06-0.1808image
ENSG00000232931.4,LINC00342COADEAGB_cells_memory1.9383e-02-0.2312image
ENSG00000232931.4,LINC00342DLBCEAGEosinophils3.4744e-040.7197image
chr2:95815308-95815905:-ESCAEERB_cells_naive3.8238e-02-0.2431image
ENSG00000232931.4,LINC00342GBMEAGNK_cells_resting7.8180e-03-0.2918image
chr2:95815308-95815905:-HNSCEERT_cells_gamma_delta8.3575e-040.5132image
ENSG00000232931.4,LINC00342HNSCEAGT_cells_gamma_delta4.0423e-020.3176image
ENSG00000232931.4,LINC00342KIRPEAGB_cells_naive4.0734e-020.2507image
chr2:95815308-95815905:-LAMLEERT_cells_regulatory_(Tregs)2.3113e-030.3122image
ENSG00000232931.4,LINC00342LAMLEAGPlasma_cells3.6046e-020.2029image
chr2:95815308-95815905:-LGGEERMacrophages_M11.8550e-030.1911image
ENSG00000232931.4,LINC00342LGGEAGNeutrophils1.7512e-020.1411image
chr2:95808691-95809194:-LUADEERB_cells_memory6.4472e-050.3637image
chr2:95815308-95815905:-LUADEERT_cells_CD81.5656e-020.1628image
ENSG00000232931.4,LINC00342LUADEAGNK_cells_resting7.0824e-030.1713image
chr2:95815308-95815905:-LUSCEERB_cells_naive2.3637e-02-0.1933image
chr2:95815308-95815905:-OVEERB_cells_memory4.9641e-030.2802image
ENSG00000232931.4,LINC00342OVEAGB_cells_memory5.6333e-030.2736image
chr2:95808691-95809194:-PAADEEREosinophils1.4297e-02-0.3257image
chr2:95815308-95815905:-PAADEERT_cells_gamma_delta1.6280e-020.2217image
ENSG00000232931.4,LINC00342PAADEAGT_cells_CD4_memory_resting1.0608e-020.2209image
chr2:95815308-95815905:-PCPGEERT_cells_CD4_memory_resting2.4867e-02-0.1785image
ENSG00000232931.4,LINC00342PCPGEAGT_cells_CD4_memory_resting3.7688e-02-0.1655image
ENSG00000232931.4,LINC00342PRADEAGT_cells_CD4_memory_resting7.5153e-030.2160image
ENSG00000232931.4,LINC00342READEAGDendritic_cells_resting4.4249e-020.3525image
chr2:95815308-95815905:-SKCMEERMacrophages_M09.2693e-030.2470image
ENSG00000232931.4,LINC00342SKCMEAGMacrophages_M01.5998e-020.2282image
chr2:95815308-95815905:-STADEERDendritic_cells_activated3.9044e-03-0.2477image
ENSG00000232931.4,LINC00342STADEAGMast_cells_activated1.5987e-02-0.2048image
ENSG00000232931.4,LINC00342TGCTEAGMacrophages_M21.0279e-02-0.4114image
ENSG00000232931.4,LINC00342THCAEAGMacrophages_M08.6961e-03-0.2721image
ENSG00000232931.4,LINC00342THYMEAGMast_cells_resting5.8381e-040.3982image
ENSG00000232931.4,LINC00342UCECEAGT_cells_follicular_helper7.5725e-030.3596image


Top

6. Enriched editing regions and immune gene sets for LINC00342


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000232931.4,LINC00342BRCAEAG8.2923e-060.17161.7072e-030.12121.3195e-020.09594.1113e-020.0791image
chr2:95815308-95815905:-BRCAEER3.6008e-050.16181.4143e-030.12536.3605e-030.10724.7821e-020.0779image
ENSG00000232931.4,LINC00342PRADEAG2.0526e-02-0.18788.9495e-03-0.21148.8299e-03-0.21171.4362e-020.1982image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr2:95808691-95809194:-BRCAGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER3.5870e-030.2446image
chr2:95815308-95815905:-BRCAGSVA_HALLMARK_MTORC1_SIGNALINGEER4.7624e-100.2418image
ENSG00000232931.4,LINC00342BRCAGSVA_HALLMARK_GLYCOLYSISEAG1.2019e-070.2032image
chr2:95808691-95809194:-CESCGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER2.6610e-02-0.4045image
ENSG00000232931.4,LINC00342CESCGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG2.6996e-020.2002image
ENSG00000232931.4,LINC00342COADGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.6797e-030.3073image
ENSG00000232931.4,LINC00342DLBCGSVA_HALLMARK_IL2_STAT5_SIGNALINGEAG6.4836e-030.5872image
ENSG00000232931.4,LINC00342ESCAGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.8224e-020.2685image
chr2:95815308-95815905:-ESCAGSVA_HALLMARK_NOTCH_SIGNALINGEER2.7922e-020.2574image
ENSG00000232931.4,LINC00342GBMGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.6888e-02-0.2632image
ENSG00000232931.4,LINC00342HNSCGSVA_HALLMARK_E2F_TARGETSEAG9.9155e-03-0.3936image
chr2:95815308-95815905:-HNSCGSVA_HALLMARK_E2F_TARGETSEER7.4704e-03-0.4219image
chr2:95815308-95815905:-LAMLGSVA_HALLMARK_COAGULATIONEER1.4375e-030.3258image
ENSG00000232931.4,LINC00342LAMLGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.4345e-02-0.2361image
chr2:95815308-95815905:-LGGGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER2.9449e-080.3336image
ENSG00000232931.4,LINC00342LUADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG1.7165e-020.1518image
chr2:95808691-95809194:-LUADGSVA_HALLMARK_APICAL_SURFACEEER6.9094e-030.2506image
chr2:95815308-95815905:-LUADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER1.7574e-050.2851image
chr2:95815308-95815905:-LUSCGSVA_HALLMARK_MTORC1_SIGNALINGEER1.6008e-060.3966image
ENSG00000232931.4,LINC00342LUSCGSVA_HALLMARK_MTORC1_SIGNALINGEAG4.9728e-050.3314image
ENSG00000232931.4,LINC00342MESOGSVA_HALLMARK_KRAS_SIGNALING_DNEAG3.6366e-02-0.3902image
ENSG00000232931.4,LINC00342OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG7.7504e-050.3829image
chr2:95815308-95815905:-OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER1.0847e-040.3792image
chr2:95815308-95815905:-PAADGSVA_HALLMARK_SPERMATOGENESISEER1.4360e-020.2258image
chr2:95808691-95809194:-PAADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER2.8118e-03-0.3920image
ENSG00000232931.4,LINC00342PAADGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG9.2020e-04-0.2841image
ENSG00000232931.4,LINC00342PCPGGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG2.5768e-020.1774image
chr2:95815308-95815905:-PCPGGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER1.3340e-020.1965image
ENSG00000232931.4,LINC00342PRADGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG4.3490e-050.3252image
chr2:95815308-95815905:-SARCGSVA_HALLMARK_P53_PATHWAYEER8.4984e-050.4044image
ENSG00000232931.4,LINC00342SARCGSVA_HALLMARK_ANGIOGENESISEAG1.4197e-040.3905image
ENSG00000232931.4,LINC00342SKCMGSVA_HALLMARK_UV_RESPONSE_DNEAG5.2027e-030.2635image
chr2:95815308-95815905:-SKCMGSVA_HALLMARK_MYOGENESISEER3.1000e-030.2796image
chr2:95815308-95815905:-STADGSVA_HALLMARK_MYOGENESISEER4.6620e-030.2430image
ENSG00000232931.4,LINC00342STADGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.0346e-02-0.2176image
ENSG00000232931.4,LINC00342TGCTGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG2.1315e-04-0.5659image
ENSG00000232931.4,LINC00342THCAGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG1.4956e-040.3852image
ENSG00000232931.4,LINC00342THYMGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.2467e-06-0.5389image
ENSG00000232931.4,LINC00342UCECGSVA_HALLMARK_DNA_REPAIREAG2.7587e-030.3996image
chr2:95815308-95815905:-UCSGSVA_HALLMARK_DNA_REPAIREER1.3267e-030.5507image
ENSG00000232931.4,LINC00342UCSGSVA_HALLMARK_DNA_REPAIREAG2.8106e-030.5184image


Top

7. Enriched editing regions and drugs for LINC00342


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000232931.4,LINC00342BLCAAZD6482EAG3.5946e-020.2670image
chr2:95808691-95809194:-BRCABosutinibEER2.2938e-02-0.1922image
chr2:95815308-95815905:-BRCACCT007093EER6.7454e-060.1761image
ENSG00000232931.4,LINC00342BRCACCT007093EAG1.9692e-070.1998image
ENSG00000232931.4,LINC00342CESCGDC0941EAG1.2742e-02-0.2249image
chr2:95808691-95809194:-CESCAZD.0530EER1.5434e-020.4382image
ENSG00000232931.4,LINC00342COADJNJ.26854165EAG3.9583e-02-0.2041image
ENSG00000232931.4,LINC00342DLBCKIN001.135EAG1.8711e-02-0.5202image
ENSG00000232931.4,LINC00342ESCABicalutamideEAG8.7402e-03-0.2969image
chr2:95815308-95815905:-ESCAKIN001.135EER1.7787e-03-0.3596image
ENSG00000232931.4,LINC00342HNSCKU.55933EAG3.4602e-04-0.5261image
chr2:95815308-95815905:-HNSCAZD6244EER2.1039e-04-0.5599image
ENSG00000232931.4,LINC00342KIRPCCT007093EAG9.3201e-030.3154image
ENSG00000232931.4,LINC00342LAMLCI.1040EAG1.8670e-020.2271image
chr2:95815308-95815905:-LAMLAG.014699EER1.3116e-030.3284image
chr2:95815308-95815905:-LGGBAY.61.3606EER4.3384e-060.2790image
ENSG00000232931.4,LINC00342LGGDMOGEAG1.9978e-020.1383image
ENSG00000232931.4,LINC00342LUADCCT007093EAG2.9217e-020.1391image
chr2:95815308-95815905:-LUADAZD8055EER6.7987e-04-0.2274image
chr2:95815308-95815905:-LUSCBortezomibEER1.6732e-03-0.2661image
ENSG00000232931.4,LINC00342LUSCDocetaxelEAG1.4827e-02-0.2027image
ENSG00000232931.4,LINC00342MESOCyclopamineEAG2.4770e-02-0.4161image
chr2:95815308-95815905:-OVA.770041EER3.3281e-05-0.4042image
ENSG00000232931.4,LINC00342OVImatinibEAG2.5853e-050.4056image
chr2:95815308-95815905:-PAADCGP.082996EER3.6912e-030.2664image
ENSG00000232931.4,LINC00342PAADJNJ.26854165EAG7.5901e-040.2885image
chr2:95808691-95809194:-PAADBleomycinEER1.5626e-020.3217image
chr2:95815308-95815905:-PCPGIPA.3EER1.6645e-040.2952image
ENSG00000232931.4,LINC00342PCPGIPA.3EAG6.7804e-040.2675image
ENSG00000232931.4,LINC00342PRADAG.014699EAG3.5806e-03-0.2349image
ENSG00000232931.4,LINC00342READLenalidomideEAG3.1300e-02-0.3755image
chr2:95815308-95815905:-SARCCI.1040EER1.2727e-03-0.3363image
ENSG00000232931.4,LINC00342SARCCisplatinEAG1.9063e-03-0.3229image
chr2:95815308-95815905:-SKCMEmbelinEER3.9151e-03-0.2729image
ENSG00000232931.4,LINC00342SKCMEmbelinEAG2.4424e-03-0.2849image
chr2:95815308-95815905:-STADGNF.2EER4.7713e-06-0.3836image
ENSG00000232931.4,LINC00342STADGSK269962AEAG1.1987e-03-0.2739image
ENSG00000232931.4,LINC00342TGCTCGP.082996EAG3.7761e-04-0.5472image
ENSG00000232931.4,LINC00342THCABIRB.0796EAG1.0940e-020.2642image
ENSG00000232931.4,LINC00342THYMBAY.61.3606EAG5.8912e-090.6245image
ENSG00000232931.4,LINC00342UCECBortezomibEAG9.0064e-04-0.4389image
ENSG00000232931.4,LINC00342UCSAS601245EAG5.1526e-030.4899image
chr2:95815308-95815905:-UCSAS601245EER4.0381e-030.5016image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType